Contact
searchSearch
HMP Global
Login

Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Tony S Mok, MD, FRCPC, FASCO
Videos
Lorlatinib Continues to Show Benefit as First-Line Treatment for Advanced ALK+ Non-Small Cell Lung Cancer
06/22/2026
Tony S. Mok, MD, FRCPC, FASCO
Tony S Mok, MD, FRCPC, FASCO, discusses the 7-year update from the phase 3 CROWN trial evaluating first-line lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer. The study previously demonstrated a...
Tony S Mok, MD, FRCPC, FASCO, discusses the 7-year update from the phase 3 CROWN trial evaluating first-line lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer. The study previously demonstrated a...
Tony S Mok, MD, FRCPC, FASCO,...
06/22/2026
Oncology
Joel Neal, MD
Videos
Amivantamab Plus Lazertinib Improves Survival in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer
06/18/2026
Joel Neal, MD
Joel Neal, MD, discusses updated results from CHRYSALIS-2 Cohort C evaluating first-line amivantamab plus lazertinib in patients with atypical EGFR-mutated advanced NSCLC.
Joel Neal, MD, discusses updated results from CHRYSALIS-2 Cohort C evaluating first-line amivantamab plus lazertinib in patients with atypical EGFR-mutated advanced NSCLC.
Joel Neal, MD, discusses updated...
06/18/2026
Oncology
Jamie Chaft, MD
Videos
Adjuvant Nivolumab Fails to Improve DFS Regardless of PD-L1 Status in Non-Small Cell Lung Cancer
06/10/2026
Jamie Chaft, MD
Jamie Chaft, MD, discusses results from the phase 3 EA5142 trial, part of the National Cancer Institute’s ALCHEMIST program, evaluating adjuvant nivolumab in patients with resected EGFR or ALK-negative NSCLC following standard therapy.
Jamie Chaft, MD, discusses results from the phase 3 EA5142 trial, part of the National Cancer Institute’s ALCHEMIST program, evaluating adjuvant nivolumab in patients with resected EGFR or ALK-negative NSCLC following standard therapy.
Jamie Chaft, MD, discusses...
06/10/2026
Oncology
Lyudmila Bazhenova, MD
Videos
Taletrectinib for ROS1-Positive Non-Small Cell Lung Cancer
05/12/2026
Lyudmila Bazhenova, MD
Lyudmila Bazhenova, MD, discusses results from the TRUST-I and TRUST-II trials assessing taletrectinib in ROS1-positive non-small cell lung cancer.
Lyudmila Bazhenova, MD, discusses results from the TRUST-I and TRUST-II trials assessing taletrectinib in ROS1-positive non-small cell lung cancer.
Lyudmila Bazhenova, MD,...
05/12/2026
Oncology
Lyudmila Bazhenova, MD
Videos
Taletrectinib Demonstrates Long-Term Durability in ROS1-Positive Non-Small Cell Lung Cancer
05/04/2026
Lyudmila Bazhenova, MD
Lyudmila Bazhenova, MD, discusses updated results from the TRUST-I and TRUST-II trials assessing taletrectinib in TKI-naive patients with ROS1-positive non-small cell lung cancer.
Lyudmila Bazhenova, MD, discusses updated results from the TRUST-I and TRUST-II trials assessing taletrectinib in TKI-naive patients with ROS1-positive non-small cell lung cancer.
Lyudmila Bazhenova, MD,...
05/04/2026
Oncology
Estelamari Rodriguez, MD
Videos
Perioperative Immunotherapy for Patients With Resectable Non-Small Cell Lung Cancer
03/15/2026
Estelamari Rodriguez, MD, MPH
Estelamari Rodriguez, MD, discusses the importance of continuing immunotherapy after surgery to maintain immune activation and reduce recurrence risk in patients with early-stage resectable non-small cell lung cancer.
Estelamari Rodriguez, MD, discusses the importance of continuing immunotherapy after surgery to maintain immune activation and reduce recurrence risk in patients with early-stage resectable non-small cell lung cancer.
Estelamari Rodriguez, MD,...
03/15/2026
Oncology
Kelsey Pan, MD
Videos
Defining the Optimal Immunotherapy Strategy in Resectable Non-Small Cell Lung Cancer
03/14/2026
Kelsey Pan, MD
Kelsey Pan, MD, discusses whether a neoadjuvant-only immunotherapy approach may be sufficient for patients with resectable non-small cell lung cancer.
Kelsey Pan, MD, discusses whether a neoadjuvant-only immunotherapy approach may be sufficient for patients with resectable non-small cell lung cancer.
Kelsey Pan, MD, discusses...
03/14/2026
Oncology
Corey Langer, MD, Abramson Cancer Center
Videos
Treatment Selection for ALK-Positive Metastatic Non-Small Cell Lung Cancer
09/04/2025
Corey J. Langer, MD, FACP
Corey Langer, MD, presents a case demonstrating how liquid biopsy identified an ALK fusion and guided treatment with alectinib, resulting in durable disease control and preserved quality of life in an older patient with metastatic non-small...
Corey Langer, MD, presents a case demonstrating how liquid biopsy identified an ALK fusion and guided treatment with alectinib, resulting in durable disease control and preserved quality of life in an older patient with metastatic non-small...
Corey Langer, MD, presents a...
09/04/2025
Oncology
David Spigel, MD, Sarah Cannon Research Institute
Videos
Molecular Assay May Predict Patients With Non-Small Cell Lung Cancer to Benefit From Adjuvant Therapy
06/16/2025
David Spigel, MD
David Spigel, MD, discusses the results of the AIM-HIGH trial to evaluating the predictive efficacy of a 14-gene expression profile in identifying stage Ia to IIa patients with non-squamous NSCLC who benefit from adjuvant therapy.
David Spigel, MD, discusses the results of the AIM-HIGH trial to evaluating the predictive efficacy of a 14-gene expression profile in identifying stage Ia to IIa patients with non-squamous NSCLC who benefit from adjuvant therapy.
David Spigel, MD, discusses the...
06/16/2025
Oncology Learning Network APP Institute
Joshua Sabari, MD
Videos
Zongertinib for Previously Treated Patients With HER2-Mutant Advanced Non-Small Cell Lung Cancer
05/22/2025
Joshua Sabari, MD
Joshua Sabari, MD, discusses results from the phase 1a/1b Beamion LUNG-1 trial evaluating zongertinib among previously treated patients with HER2-mutant advanced non-small cell lung cancer.
Joshua Sabari, MD, discusses results from the phase 1a/1b Beamion LUNG-1 trial evaluating zongertinib among previously treated patients with HER2-mutant advanced non-small cell lung cancer.
Joshua Sabari, MD, discusses...
05/22/2025
Oncology

Recent News

FDA Approval
FDA Approves Neoadjuvant/Adjuvant Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer
10/03/2024
Stephanie Holland
Based on results from the CHECKMATE-77T trial, the FDA has approved nivolumab plus platinum-doublet chemotherapy followed by surgical resection and single-agent nivolumab for patients with non-small cell lung cancer with no known EGFR...
Based on results from the CHECKMATE-77T trial, the FDA has approved nivolumab plus platinum-doublet chemotherapy followed by surgical resection and single-agent nivolumab for patients with non-small cell lung cancer with no known EGFR...
Based on results from the...
10/03/2024
Oncology
News
Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma
06/26/2026
Emily Estrada
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an...
06/26/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients...
06/25/2026
Oncology
News
Pirtobrutinib Demonstrates Durable Clinical Activity in Relapsed or Refractory Waldenström Macroglobulinemia
06/25/2026
Stephanie Holland
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN...
06/25/2026
Oncology
News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Bulumtatug Fuvedotin Demonstrates Durable Activity in Previously Treated Cervical Cancer
06/23/2026
Emily Estrada
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2...
06/23/2026
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Patients With Unresectable or Metastatic Synovial Sarcoma
06/23/2026
Stephanie Holland
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the...
06/23/2026
Oncology
News
Signatera-Based ctDNA Testing Incorporated Into NCCN Bladder Cancer Guidelines
06/23/2026
Stephanie Holland
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use